To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population.
Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires.
Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service.
To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.
JCO global oncology. 2022 Nov [Epub]
Lorelei A Mucci, Jacob Vinson, Theresa Gold, Travis Gerke, Julie Filipenko, Rebecca M Green, Simon G Anderson, Simone Badal, Anders Bjartell, Kim N Chi, Ian D Davis, Deborah Enting, André P Fay, John Lazarus, Joaquin Mateo, Ray McDermott, Folakemi T Odedina, David Olmos, Aurelius Omlin, Ademola A Popoola, Camille Ragin, Robin Roberts, Kjell M Russnes, Charles Waihenya, Konrad H Stopsack, Terry Hyslop, Paul Villanti, Philip W Kantoff, Daniel J George, IRONMAN Global Team
Harvard T.H. Chan School of Public Health, Boston, MA., Prostate Cancer Clinical Trials Consortium, New York, NY., The Glasgow-Caribbean Centre for Development Research and the Caribbean Institute of Health Research, The University of the West Indies, Bridgetown, Barbados., The University of the West Indies Mona, Kingston, Jamaica., Skåne University Hospital, Malmö, Sweden., BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Monash University, Melbourne, Australia., Guys St Thomas NHS Foundation Trust, London, United Kingdom., Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil., University of Cape Town, Cape Town, South Africa., Vall d'Hebron Institute of Oncology, Barcelona, Spain., St Vincent's University Hospital & Cancer Trials Ireland, Dublin, Ireland., Mayo Clinic, Jacksonville, FL., Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain., Kantonsspital St Gallen, St Gallen, Switzerland., University of Ilorin, Ilorin, Nigeria., Fox Chase Cancer Center, Philadelphia, PA., UWI School of Clinical Medicine and Research, Nassau, The Bahamas., Oslo University Hospital, Oslo, Norway., University of Nairobi, Nairobi, Kenya., Duke Cancer Institute, Durham, NC., Movember Foundation, Melbourne, Australia., Convergent Therapeutics, Cambridge, MA.